Insitro logo

Scientist II, Neuroscience, Translational Medicine - Insitro

View Company Profile
Job Title
Scientist II, Neuroscience, Translational Medicine
Job Location
South San Francisco, CA
Job Description

The Opportunity

The heart of insitro’s strategy is the combination of novel, cutting edge methods in machine learning, biology at scale and small molecule discovery that address key bottlenecks in the drug development pipeline. To accomplish that, we are putting together an incredible team of highly talented translational scientists who want to make a difference to this important problem. The Scientist II, Translational Medicine  will be responsible for leading and/or executing in vivo studies focused on characterizing the efficacy and safety of novel therapeutics/drugs to advance insitro’s development pipeline. Specifically, the candidate will work in a cross-functional, multi-disciplinary environment to establish proof-of-concept, pharmacokinetic and pharmacodynamic relationships, and safety/toxicology for therapeutics/drugs in relevant animal models with a focus on neurological disease. A successful candidate will be flexible, collaborative, innovative, and rigorous and will thrive in a dynamic, exciting, and high-impact environment.      

In broader context, you will be joining a growing biotech startup that has long-term stability due to significant funding, but yet is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!

 Primary Responsibilities 

  • Evaluation and prioritization of relevant in vivo models to assess predictive validity for neurological diseases and disorders. 
  • Evaluation and prioritization of different therapeutic modalities, routes of administration, and mechanisms of action for in vivo models of neurological diseases and disorders.  
  • Evaluation and prioritization of different endpoints/biomarkers that translate from in vivo studies to clinical trials.
  • Design, execution, interpretation, and reporting of in vivo studies covering proof-of-concept, pharmacokinetics, pharmacodynamics, and/or safety/toxicology. 


About You

  • MD, MD/PhD, or PhD with 4+ years of experience in in vivo studies focused on proof-of-concept, PK/PD, and/or safety/toxicology
  • Experience with evaluating, prioritizing, and characterizing in vivo models 
  • Experience with and knowledge of the process of therapeutic/drug evaluation from early to late phases of non-clinical development 
  • Experience with and knowledge of working in standardized and protocolized environments (e.g. good lab practice, GLP)
  • Experience evaluating, engaging, establishing, and partnering with contract research organizations (CROs) 


Nice to Have 

  • Experience and knowledge of neurological and psychiatric disorders and in vivo animal models  with an emphasis on epileptic, neurodegenerative, and cognitive disorders
  • Experience with investigational new drug (IND) submissions, particularly in auditing, approving study reports and preparing non-clinical summaries 
  • Experience with evaluating, selecting, and qualifying/validating biomarkers 
  • Experience with established or novel bioanalytical, molecular, or histological assays to inform in vivo studies
  • Experience with early phase clinical trials to inform non-clinical strategy
Compensation & Benefits at insitro
Our target starting salary for successful US-based applicants for this role is $125,000 - $145,000 To determine starting pay, we consider multiple job-related factors including a candidate’s skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data. 
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
  • 401(k) plan with employer matching for contributions
  • Excellent medical, dental, and vision coverage (insitro pays 100% of premiums for employees), as well as mental health and well-being support
  • Open, flexible vacation policy
  • Paid parental leave
  • Quarterly budget for books and online courses for self-development
  • Support to occasionally attend professional conferences that are meaningful to your career growth and development
  • New hire stipend for home office setup
  • Monthly cell phone & internet stipend
  • Access to free onsite baristas and cafe with daily lunch and breakfast
  • Access to free onsite fitness center
  • Commuter benefits
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit

Insitro Headquarters Location

South San Francisco, CA

View on map

Insitro Company Size

Between 200 - 500 employees

Insitro Founded Year


Insitro Total Amount Raised


Insitro Funding Rounds

View funding details
  • Series C

    $400,000,000 USD

  • Series B

    $143,000,000 USD

  • Series A

    $100,000,000 USD

  • Series A

    $100,000,000 USD